Academisch Ziekenhuis Maastricht
- Address
- P Debyelaan 25, 6229 HX Maastricht, The Netherlands
University Hospital Maastricht - Advanced Oncology & Multidisciplinary Research Center
University Hospital Maastricht is a leading academic medical center conducting cutting-edge clinical research across multiple therapeutic areas. The institution demonstrates particular strength in oncology research, with extensive expertise in solid tumors and hematologic malignancies, ranging from early-stage disease to advanced metastatic conditions. The center's research portfolio encompasses innovative treatment approaches including immunotherapy, targeted therapies, and personalized medicine strategies.
- Advanced cancer therapeutics including melanoma, lung cancer, breast cancer, colorectal cancer, and gastrointestinal malignancies with focus on immunotherapy and precision oncology
- Hematologic disorders including multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, and Burkitt lymphoma with novel cellular and antibody-based therapies
- Cardiovascular and renal conditions including hypertension, chronic kidney disease, cardiomyopathy, and preventive cardiology in genetic carriers
- Rare genetic disorders, transplant medicine, dermatologic conditions, and surgical innovation across multiple specialties
The hospital's multidisciplinary approach integrates biomarker-driven research with clinical outcomes, participating in pivotal international Phase II and III trials. Research initiatives span from neoadjuvant and adjuvant therapies to maintenance treatment strategies, with particular emphasis on organ preservation, quality of life, and long-term survival outcomes. The center actively contributes to breakthrough studies in CAR-T cell therapy, bispecific antibodies, and antibody-drug conjugates, while maintaining robust programs in cardiovascular disease prevention, inflammatory conditions, and regenerative medicine approaches.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 7 therapeutic areas and 15 of 62 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 62 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1Boehringer Ingelheim Espana S.A.3active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Academisch Ziekenhuis Maastricht
lock Showing 1 of 30 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-DCM). | Kardigan Inc. | Phase IV | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 62 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 6 | Unknown | 2018-11-27 | 2025-06-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.